Table 2.
Characteristics of COVID-19 and non-COVID-19 patients
| COVID-19 | Non-COVID-19 | |
|---|---|---|
| KS: patients N° | 12 | 108 |
| Group 1: patients N° | 2 | 32 |
| Group 2: patients N° | 3 | 14 |
| Group 3: patients N° | 7 | 62 |
| Age (years): median (IQ range) | 22.5 (20.3) | 19 (32) |
| BMI (pc) group 1 + 2: Mean ± DS (range) | 66.4 ± 38.1 (12–99) | 50.9 ± 37.2 (0.1–99) |
| BMI (Kg/m2) group 3: Mean ± DS (range) | 24.7 ± 3.3 (19.4–28.4) | 25.7 ± 5.8 (16.3–42.4) |
| Northern Italy N°(%) | 7 (58.3) | 73 (67.6) |
| Central Italy N°(%) | 3 (25) | 15 (13.9) |
| Southern Italy N°(%) | 2 (16.7) | 20 (18.5) |
| TRT: patients N°(%) | 7 (58.3) | 54 (50) |
| TRT in group 2: patients N°(%) | 1/7 (14.3) | 4/54 (7.4) |
| TRT in group 3: patients N°(%) | 6/7 (85.7) | 50/54 (92.6) |
| Transdermal TRT: patients N°(%) | 4 (57.1) | 27 (50) |
| Undecanoate T i.m.: patients N°(%) | 2 (28.6) | 27 (50) |
| Propionate T: patients N°(%) | 1 (14.3) | 0 |
| Plasma testosterone (ng/ml): Mean DS (Range): | 3.1 ± 1.2 (1.5–4.6)* | 5.2 ± 2 (2.6–11.5)* |
| Plasma testosterone group 2 (ng/ml): Mean ± DS (Range) | 2.2 ± 0.6 (1.5–2.6) | 4.9 ± 2.7 (2.97–10) |
| Plasma testosterone group 3 (ng/ml): Mean ± DS (Range) | 3.5 ± 0.9 (2–4.6) + | 5.2 ± 2 (2.6–11.5) + |
| Dyslipidemia group 2 + 3: patients N°(%) | 4/10 (40) | 30/76 (39.5) |
| Hypertension group 2 + 3: patients N°(%) | 4/10 (40) | 18/76 (23.7) |
| Epilepsy group 2 + 3: patients N°(%) | 0 | 5/76 (6.6) |
| DMT 2 group 2 + 3: patients N°(%) | 3/10 (30) | 6/76 (7.9) |
| OSAS group 2 + 3: patients N°(%) | 3/10 (30)+ | 5/76 (6.6)+ |
| Overweight/obesity group 1 + 2: patients N°(%) | 2 (40) /1 (20) | 7 (15.2) /4 (8.7) |
| Overweight/obesity group 3: patients N°(%) | 5 (71.4)*/0 | 11(17.7)*/17 (27.4) |
Group 1 subjects < 14 years of age, Group 2 subjects 14–17 years of age, Group 3 subjects ≥ 18 years of age, TRT Testosterone Replacement Therapy, Pc sex-specific percentiles, IQ range interquartile range
* or +: p < 0.05